Frameshift Variant in AMPD2 in Cirneco dell’Etna Dogs with Retinopathy and Tremors
Genes · 2024
DOI: 10.3390/genes15020238 ↗Kurz gefasst
Fachartikel in der Zeitschrift Genes, 2024. Verfasst von Leonardo Murgiano und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Experimental Retinal Therapies, Department of Clinical Sciences & Advanced Medicine, University of Pennsylvania, Philadelphia, PA 19104, …. Hauptthemen laut MEDLINE: AMP Deaminase, Retinal Degeneration, Tremor. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NEI NIH HHS, Van Sloun Foundation and NEI/NIH, Foundation Fighting Blindness.
Abstract (Originalsprache)
While the manifestations of many inherited retinal disorders are limited to loss of vision, others are part of a syndrome that affects multiple tissues, particularly the nervous system. Most syndromic retinal disorders are thought to be recessively inherited. Two dogs out of a litter of Cirneco dell′ Etna dogs, both males, showed signs of retinal degeneration, along with tremors and signs described as either atypical seizures or paroxysmal dyskinesias, while the other two male littermates were normal. We named this oculo-neurological syndrome CONS (Cirneco oculo-neurological syndrome), and undertook homozygosity mapping and whole-genome sequencing to determine its potential genetic etiology. Notably, we detected a 1-bp deletion in chromosome 6 that was predicted to cause a frameshift and premature stop codon within the canine AMPD2 gene, which encodes adenosine monophosphate deaminase, an enzyme that converts adenosine 5′-monophosphate (AMP) to inosine 5’-monophosphate (IMP). Genotyping of the available Cirneco population suggested perfect segregation between cases and controls for the variant. Moreover, this variant was absent in canine genomic databases comprised of thousands of unaffected dogs. The AMPD2 genetic variant we identified in dogs presents with retinal manifestations, adding to the spectrum of neurological manifestations associated with AMPD2 variants in humans.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Experimental Retinal Therapies, Department of Clinical Sciences & Advanced Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
- Sylvia M. Van Sloun Laboratory for Canine Genomic Analysis, University of Pennsylvania, Philadelphia, PA 19104, USA.
- Matthew J. Ryan Veterinary Hospital, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
- Department of Agricultural and Environmental Sciences-Production, Territory, Agroenergy, University of Milan, 20133 Milan, Italy.
- Department of Veterinary Sciences, University of Messina, 98168 Messina, Italy.
- Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
ORCID-Profile: Matteo Cortellari, Arianna Bionda, Paola Crepaldi, Luigi Liotta, Geoffrey K Aguirre
Förderung
- NEI NIH HHS
- Van Sloun Foundation and NEI/NIH
- Foundation Fighting Blindness
Zitieren
APA
Murgiano, L., Niggel, J. K., Benedicenti, L., Cortellari, M., Bionda, A., Crepaldi, P., Liotta, L., Aguirre, G. K., Beltran, W. A., & Aguirre, G. D. (2024). Frameshift Variant in AMPD2 in Cirneco dell’Etna Dogs with Retinopathy and Tremors. Genes. https://doi.org/10.3390/genes15020238
Vancouver
Murgiano L, Niggel JK, Benedicenti L, Cortellari M, Bionda A, Crepaldi P, et al. Frameshift Variant in AMPD2 in Cirneco dell’Etna Dogs with Retinopathy and Tremors. Genes. 2024. doi:10.3390/genes15020238
BibTeX
@article{Murgiano2024,
author = {Murgiano, Leonardo and Niggel, Jessica K and Benedicenti, Leontine and Cortellari, Matteo and Bionda, Arianna and Crepaldi, Paola and Liotta, Luigi and Aguirre, Geoffrey K and Beltran, William A and Aguirre, Gustavo D},
title = {Frameshift Variant in AMPD2 in Cirneco dell’Etna Dogs with Retinopathy and Tremors},
journal = {Genes},
year = {2024},
doi = {10.3390/genes15020238}
}
EUVIMED